Real symptoms and case analysis after taking afatinib (Gitari)

Afatinib is a second-generation irreversible EGFR tyrosine kinase inhibitor (TKI), mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Compared with the first-generation EGFR-TKI, afatinib can irreversibly bind to EGFR, HER2 and HER4 receptors, inhibiting downstream signaling pathways, thereby blocking cancer cell proliferation and survival. Clinical data show that afatinib is effective in improving tumor control rate and prolonging progression-free survival. However, patients often experience a series of real side effects after taking it, including rash, diarrhea, stomatitis, fatigue, and abnormal liver function.

In a real clinical case, a 58 female patient developed red papules on her face and chest, accompanied by itching, 2 weeks after taking afatinib. After dermatological evaluation, it was determined to be EGFR-TKI related rash. Doctors recommended topical corticosteroid ointment and oral antihistamines, and symptoms resolved within a week. While the patient continued to take afatinib, through regular use of skin care and topical treatments, the rash did not worsen and the drug efficacy was maintained. This case demonstrates that rashes, although common, can be effectively controlled through timely intervention and patient self-management.

Another 65 male patient developed moderate diarrhea and loss of appetite after starting to take afatinib, and the number of bowel movements per day increased to 5–6 times. Clinicians adjusted the diet (light, less fat) and used anti-diarrhea drugs (loperamide) for symptomatic treatment, while monitoring water, electrolytes and body weight. The symptoms improved significantly within about two weeks. This case shows that although the gastrointestinal reactions of afatinib are relatively common, most of them are controllable and manageable side effects. Timely intervention can avoid dehydration or affecting the course of treatment.

Generally speaking, the real side effects of afatinib are mostly concentrated on the skin and digestive system, but mild to moderate fatigue, oral ulcers, abnormal liver function, etc. may also occur. Cases show that early detection, timely treatment and communication with doctors are important measures to ensure efficacy and safety. During the period of taking the medicine, patients should regularly monitor blood routine, liver function and skin status, and pay attention to lifestyle management, such as using skin care products, maintaining a light diet and regular work and rest. Through scientific management, patients can continue to take medication while controlling side effects to achieve the best therapeutic effect.

Reference materials:https://www.drugs.com/